Clinical trials
Chronic Lung Disease clinical trials
Below are recruiting chronic lung disease clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06724315Recruiting
Studying severe COPD in Brazil
This study follows people with severe or very severe COPD to learn more about their health over time. You may qualify if your COPD causes many symptoms or frequent flare-ups.
São Paulo, São PauloAges 18 years+ - NCT07355868RecruitingEarly Phase 1
Cell therapy for COPD
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
Yiwu, ZhejiangAges 40–80 - NCT07356076Recruiting
Using electrical impedance tomography to look at lung disease
This study uses a special imaging test called electrical impedance tomography (EIT) to look at how well the lungs work in people with lung diseases like COPD, asthma, pneumonia, or long-term effects from COVID-19. It also includes healthy volunteers to compare results.
OlomoucAges 18 years+ - NCT04543461Recruiting
Lung health study for young adults in the U.S.
This study follows young adults to learn about lung health and risk factors. It may help researchers better understand how breathing symptoms and exposures affect future lung outcomes.
Birmingham, AlabamaAges 25–35 - NCT06959095RecruitingPhase 3
Depemokimab for COPD with type 2 inflammation
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
Loxahatchee Groves, FloridaAges 40–80 - NCT06961214RecruitingPhase 3
Testing a new biologic for COPD with type 2 inflammation
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Sheffield, AlabamaAges 40–80 - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06491043RecruitingPhase 2
Stem cells for COPD: safety and early effectiveness study
This trial tests whether an infusion of donor stem cells can help people with moderate to severe COPD breathe easier. If you are a current or former smoker aged 40 to 80, your symptoms are stable, and your lung function meets specific targets, you may be able to join.
New Taipei CityAges 40–80 - NCT05463133RecruitingPhase 1/Phase 2
Stem cell transplant for CGD using targeted medications and steroids-free support
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
Bethesda, MarylandAges 4–65 - NCT04118660Recruiting
Thoracic specimen registry for adults with chest conditions
This study is a “specimen registry,” meaning it collects and stores samples from adults with chest (thoracic) diseases. It may help researchers better understand lung and chest conditions and improve future testing or treatments.
Rochester, MinnesotaAges 18 years+ - NCT05192057RecruitingPhase 4
Inhaling salty steam for lung MAC infection
This trial studies whether inhaling hypertonic (very salty) saline helps treat nodular-bronchiectatic lung disease caused by Mycobacterium avium complex (MAC). It may help reduce ongoing infection and symptoms if you have the right type of MAC lung pattern and have not recently started the usual MAC treatments.
NijmegenAges 18 years+ - NCT07493629Recruiting
Study on immune status and disease control in inflammatory airway diseases
This study looks at how the immune system works and how well diseases like asthma, COPD, and others are controlled. You may join if you have one of these conditions or if you are a healthy volunteer or smoker without lung disease.
Ningbo, ZhejiangAges 18 years+ - NCT06018766RecruitingPhase 2
LAM-001 for lung transplant patients with BOS
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
San Francisco, CaliforniaAges 18 years+ - NCT06177717Recruiting
Lung Health Study for Young Adults
This study looks at how young adults' lungs work over time. It is a research visit where you'll complete breathing and other health tests to help understand lung health in people aged 25–35.
Birmingham, AlabamaAges 25–35 - NCT06368882RecruitingPhase 4
Peg-interferon for hepatitis B with fatty liver
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
NingboAges 18–60 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06817590RecruitingPhase 1
Nucleoside therapy for telomere disorders
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
Boston, MassachusettsAges 1–70 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Los Angeles, CaliforniaAges 12 years+ - NCT04722835Recruiting
Study lung immune cells in people at risk for COPD
This study looks at different lung immune cell patterns and how they work in smokers who are not yet diagnosed with COPD or asthma. It may help researchers understand why some people are more likely to develop COPD, which could guide future prevention or early treatments.
San Francisco, CaliforniaAges 40–75 - NCT07339280Enrolling by invitation
Probiotics for COPD: symptoms, lungs, and inflammation
This study tests whether taking a probiotic can improve symptoms, lung function, and inflammation in people with COPD. It is for adults with stable COPD who have not had a flare-up or treatment change in the last two months.
KarlovacAges 18 years+ - NCT05976919Recruiting
Testing different treatable traits in lung disease and controls
This study looks at “treatable traits” (specific features of lung disease) across people with chronic airflow problems, including cystic fibrosis, and compares them with healthy volunteers. You may be asked to do several breathing and exercise tests to see how well different traits can be measured and how they relate to symptoms.
Leeds, LeedsAges 18–65
Hear when a new Chronic Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic lung disease?
- Yes. Clin2 currently lists 305 recruiting chronic lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.